As the Executive Director of Cardiometabolic Trials at Baim and the principal investigator
of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT,
IMPROVE IT and RE-DUAL PCI, Dr. Cannon collaborates on research and registry
projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention. Much of his research focuses on management and prevention of acute coronary syndromes, and in partnership with others, he has helped to establish antithrombotic and interventional strategies for ACS and prevention and management of lipid abnormalities.
He has authored more than 1000 publications, reviews, and book chapters, and his contributions to cardiology have been acknowledged by the receipt of numerous awards, including those from the American College of Cardiology and the American Heart Association.
Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. After medical school at Columbia University College of Physicians and Surgeons in New York, he completed an internal medicine residency at Columbia Presbyterian Medical Center, and a cardiovascular fellowship at Brigham and Women’s Hospital.